Browsing by Subject "Endometrial hyperplasia"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Open Access
    Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium
    (Murcia : F. Hernández, 2009) Kim, Kyung Hee; Choi, Jong Sun; Choi, Yoon-La; Shin, Young Kee; Lee, Ho-chang; Seong, In Ock; Kim, Bum Kyung; Chae, Seoung Wan; Kim, Seok-Hyung; Kim, Jin Man
    CD24 is known to be an important diagnostic and prognostic marker of several major cancers affecting females. We aimed to determine CD24 expression in normal, hyperplastic, and carcinomatous endometrium and its correlation with estrogen and progesterone receptor expression. A total of 271 cases including 62 normal/atrophic endometrium cases (47/15), 127 endometrial hyperplasia cases (51/52/24, simple/complex/atypical hyperplasia), and 82 endometrial carcinoma cases were immunohistochemically analyzed by using anti-CD24, ER, and PR antibodies that were embedded on paraffin blocks. Next, we assessed the CD24 mRNA expression in these tissues by using RT-PCR. In the normal endometrium, cyclic expression of membranous CD24 was detected during the regular menstrual cycle, i.e., down-regulation in the proliferative phase and up-regulation in the secretory phase. CD24 expression was very infrequent and weak in the atrophic endometrium. In hyperplasias and carcinomas, the expression of both membranous and cytoplasmic CD24 was found to be sharply reduced in the hyperplastic lesions and significantly enhanced in the carcinomas. In the case of carcinomas, high CD24 expression showed significant correlation with high-grade (G2 and 3) (P<0.05). In addition, an inverse correlation was apparent between CD24 and the estrogen and progesterone receptor expressions in normal and diseased endometrium. In conclusion, we demonstrated that CD24 was expressed in a cyclic pattern in the normal endometrium, and its expression was enhanced in case of endometrial carcinoma. These results suggest that CD24 may be involved in tumor progression and can be a useful diagnostic biomarker.
  • Thumbnail Image
    Publication
    Open Access
    Expression of a putative stem cell marker Musashi-1 in endometrium
    (F. Hernández y J.F. Madrid. Murcia: Universidad de Murcia, Departamento de Biología Celular e Histología., 2011) Lu, Xiaoye; Lin, Fangfang; Fang, Huijuan; Yang, Xuesong; Qin, Li
    Aim: Firstly to examine the expression characteristics of Musashi (Msi)-1 in fetal endometrium, reproductive normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma, next, to focus on exploring the possibility that Msi-1 serves as a marker of the endometrial stem cells in-situ. Methods: Immunohistochemical staining was performed to detect the expression of Msi-1 in 20 cases of fetal endometrium, 20 cases of normal endometrium, 20 cases of endometrial hyperplasia and 50 cases of endometrioid adenocarcinoma respectively. Results: In fetal endometrium, Msi-1 positive cells were observed from the 12th week in epithelium, but the number of Msi-1 positive cells decreased with an increase in gestational age. In reproductive normal endometrium, Msi-1 expression presented as dispersed single cell and cell groups in the stroma adjacent to the myometrium. In endometrial hyperplasia and endometrioid adenocarcinoma, Msi-1 expression significantly increased and was more widely distributed. Conclusions: Msi-1 positive cells mainly lie in the stroma of normal endometrium, and the distribution pattern is consistent with that of the speculated endometrial stem cells. The high expression of Msi-1 in fetal endometrium and endometrioid adenocarcinoma suggests that Msi-1 positive cells have several characteristics of stem cells, such as high proliferative potentiality and multipotency. Considering these factors, this makes Msi-1 potentially a promising stem cell marker.
  • Thumbnail Image
    Publication
    Open Access
    Simultaneous uterine leiomyoma and endometrial hiperplasia in a white-nosed monkey (cercopithecus nictitans). First case report
    (Murcia, Universidad de Murcia, Servicio de Publicaciones, 2010) Ibáñez, Carla; Corpa, Juan M.; Martínez Cáceres, Carlos Manuel; Facultad de Veterinaria
    This paper describes histopathological and immunocytochemical features of a combined uterine leyomioma and a non atypical complex endometrial hyperplasia in a white-nosed monkey (Cercopithecus nictitans). Immunocytochemically, uterine leiomyoma was a-actin positive, and negative for desmin. By the other hand, endometrial hyperplasia showed strong immunoreaction against ciclin D1, cyclooxygenase-2 (COX-2), oestrogen receptor, isoform A of progesterone receptor and slight p53 immunoreaction. This is the first immunocytochemical description of an endometrial hyperplasia in a white-nosed monkey. This lesional spectrum, similar to those described in human pathology, suggests similar pathogenic mechanisms
  • Thumbnail Image
    Publication
    Open Access
    The usefulness of p16 and COX-2 expression on the prediction of progression to endometrial cancer
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Kalkan, Hande Ece; Akman, Levent; Serin, Gurdeniz; Terek, Mustafa Cosan; Zekioglu, Osman; Ozsaran, Ahmet Aydin
    Objectives. Endometrial cancer (EC) is the most commonly diagnosed gynecological cancer. Endometrial hyperplasia (EH) is a more common diagnosis than EC. Endometrial hyperplasia is found in approximately 1.5% of all women presenting with abnormal bleeding. Endometrial hyperplasia progresses to EC, and especially, cancer risk increases in cases with atypical hyperplasia. p16, one of the tumor suppressor proteins involved in the cell cycle, and COX-2, one of the key enzymes of prostaglandin synthesis, are important markers for the diagnosis of both EH and EC. There is lack of consensus in the classification, diagnosis and treatment of EH. The subject of changes in the cell cycle in the progression of endometrial pathologies may help to identify and prevent these affected pathways in the treatment stage. The aim of this study is to investigate the expression of p16 and COX-2 during the development of EC from EH. Material and methods. We investigated COX-2 and P16 expressions in patients with proliferative endometrium, complex/simple endometrial hyperplasia and endometrioid adenocarcinoma. Results. p16 expression increased in EH and EC (p<0.001). COX-2 expression was increased in endometrial cancer compared to other groups, but this increase was not found to be statistically significant. Although p16 and COX-2 expression were increased in patients with advanced grade/stage, lymphovascular invasion, and >50% of myometrial invasion, this increase was not statistically significant. Conclusions. More detailed studies are needed to investigate the prognostic significance of the COX-2 molecule. COX-2 might be a potential biomarker for the prognosis of endometrial cancer and a potential therapeutic target for EC treatment. Also, it might be used to prevent the progression of precursor lesions to invasive EC.